Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The most studied biological role of type III interferons (IFNs) has so far been their antiviral activity, but their role in autoimmune and inflammatory diseases remains largely unexplored. Here, we show that treatment with IFN-λ2/IL-28A completely halts and reverses the development of collagen-induced arthritis (CIA) and discover cellular and molecular mechanisms of IL-28A antiinflammatory function. We demonstrate that treatment with IL-28A dramatically reduces numbers of proinflammatory IL-17-producing Th17 and γδ T cells in the joints and inguinal lymph nodes, without affecting T cell proliferative responses or levels of anticollagen antibodies. IL-28A exerts its antiinflammatory effect by restricting recruitment of IL-1b-expressing neutrophils, which are important for amplification of inflammation. We identify neutrophils as cells expressing high levels of IFN-λ receptor 1 (IFNLR1)-IL-28 receptor α (IL28RA) and targeted by IL-28A. Our data highlight neutrophils as contributors to the pathogenesis of autoimmune arthritis and present IFN-λs or agonists of IFNLR1-IL28RA as putative new therapeutics for neutrophil-driven inflammation.

Original publication

DOI

10.1084/jem.20140995

Type

Journal article

Journal

J Exp Med

Publication Date

01/06/2015

Volume

212

Pages

845 - 853

Keywords

Animals, Arthritis, CD4-Positive T-Lymphocytes, Cattle, Cell Movement, Cell Proliferation, Chickens, Collagen, Flow Cytometry, Gene Expression Regulation, Inflammation, Interleukin-17, Interleukin-1beta, Interleukins, Male, Mice, Mice, Inbred C57BL, Mice, Inbred DBA, Neutrophils, Receptors, Antigen, T-Cell, gamma-delta, Receptors, Cytokine, T-Lymphocytes